Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice

A westernized high-fat diet (HFD) is associated with the development of inflammatory bowel disease (IBD). High-level fecal deoxycholic acid (DCA) caused by HFD contributes to the colonic inflammatory injury of IBD; however, the mechanism concerning the initiation of inflammatory response by DCA rema...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 7; p. 536
Main Authors Zhao, Shengnan, Gong, Zizhen, Zhou, Jiefei, Tian, Chunyan, Gao, Yanhong, Xu, Congfeng, Chen, Yingwei, Cai, Wei, Wu, Jin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.11.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A westernized high-fat diet (HFD) is associated with the development of inflammatory bowel disease (IBD). High-level fecal deoxycholic acid (DCA) caused by HFD contributes to the colonic inflammatory injury of IBD; however, the mechanism concerning the initiation of inflammatory response by DCA remains unclear. In this study, we sought to investigate the role and mechanism of DCA in the induction of inflammation promoting NLRP3 inflammasome activation. Here, we, for the first time, showed that DCA dose-dependently induced NLRP3 inflammasome activation and highly pro-inflammatory cytokine-IL-1β production in macrophages. Mechanistically, DCA-triggered NLRP3 inflammasome activation by promoting cathepsin B release at least partially through sphingosine-1-phosphate receptor 2. Colorectal instillation of DCA significantly increased mature IL-1β level in colonic tissue and exacerbated DSS-induced colitis, while blockage of NLRP3 inflammasome or macrophage depletion dramatically reduced the mature IL-1β production and ameliorated the aggravated inflammatory injury imposed by DCA. Thus, our findings show that high-level fecal DCA may serve as an endogenous danger signal to activate NLRP3 inflammasome and contribute to HFD-related colonic inflammation. NLRP3 inflammasome may represent a new potential therapeutical target for treatment of IBD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Nobuhiko Kamada, University of Michigan Health System, USA; Alberto Finamore, Consiglio per la ricerca in agricoltura e l’analisi dell’economia agraria (CREA), Italy
Edited by: Lorraine M. Sordillo, Michigan State University, USA
Specialty section: This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2016.00536